Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Senzime AB ( (SE:SEZI) ).
Senzime AB has successfully completed the full subscription of its directed share issue, raising MSEK 110 through the issuance of 24,000,000 shares. This capital increase will support the company’s growth, resulting in a 15.27% dilution of shares, and reflects strong investor confidence in Senzime’s market position and future prospects.
More about Senzime AB
Senzime is a leading medical device company based in Uppsala, Sweden, specializing in precision-based monitoring systems that enhance perioperative patient safety. Their flagship product, the TetraGraph® system, is renowned for its accuracy in monitoring neuromuscular transmission during surgery, contributing to improved patient outcomes and cost reductions. Senzime is publicly traded on the Nasdaq Stockholm Main Market and the US OTCQX Market.
Average Trading Volume: 330,142
Current Market Cap: SEK845.2M
For detailed information about SEZI stock, go to TipRanks’ Stock Analysis page.